CRDL vs. HLS, CPH, OGI, ACB, GUD, MDNA, HTL, QIPT, EDT, and ONC
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include HLS Therapeutics (HLS), Cipher Pharmaceuticals (CPH), Organigram (OGI), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Medicenna Therapeutics (MDNA), Hamilton Thorne (HTL), Quipt Home Medical (QIPT), Spectral Medical (EDT), and Oncolytics Biotech (ONC). These companies are all part of the "medical" sector.
Cardiol Therapeutics (TSE:CRDL) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
Cardiol Therapeutics has a net margin of 0.00% compared to HLS Therapeutics' net margin of -43.65%. HLS Therapeutics' return on equity of -24.69% beat Cardiol Therapeutics' return on equity.
HLS Therapeutics received 25 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 68.00% of users gave HLS Therapeutics an outperform vote.
Cardiol Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
HLS Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, HLS Therapeutics had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for HLS Therapeutics and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.63 beat HLS Therapeutics' score of -0.70 indicating that Cardiol Therapeutics is being referred to more favorably in the media.
13.0% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of HLS Therapeutics shares are owned by institutional investors. 4.4% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 0.5% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
HLS Therapeutics has a consensus price target of C$3.88, suggesting a potential downside of 1.90%. Given HLS Therapeutics' higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.
Summary
HLS Therapeutics beats Cardiol Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
